LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Legal & Regulatory and Reimbursement/FDA Clears TKA System With Novel UHMWPE Crosslinked Surface
Legal & Regulatory and Reimbursement

FDA Clears TKA System With Novel UHMWPE Crosslinked Surface

February 1, 2023 2 min read Premium comments

Advertisement

FDA Clears TKA System With Novel UHMWPE Crosslinked Surface
Klassic® Knee System / Courtesy of Total Joint Orthopedics, Inc.
Secondary#klassickneesystem#totaljointorthopedics#uhmwpe

The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to a knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis.

According to the 510(k) summary document, the knee system is intended for “prosthetic replacement in treatment of the following:

  • Patient conditions of non-inflammatory degenerative joint disease (NIDJD): avascular necrosis and osteoarthritis
  • Patient conditions of inflammatory joint disease (IJD): rheumatoid arthritis
  • Patients with failed previous surgery where pain, deformity, or dysfunction persists
  • Correctable varus-valgus deformity and moderate flexion contracture
  • Revision of a previously failed knee arthroplasty
  • Patients who require a total knee replacement.”

The manufacturer of the system, Salt Lake City based Total Joint Orthopedics, Inc. (TJO), has introduced a number of truly novel joint reconstruction implants which are differentiated by their advanced materials technologies.

The brand name for this novel total knee implant is Klassic® Knee System.

According to the company’s 510(k) summary document, the Klassic Knee System is indicated for “cemented use only, except for the Klassic Femur with Cobalt 3D™, and the Klassic Tibial Baseplate with Ti-Coat®, which are indicated for cementless use.”

The Klassic Knee System includes Alchimist, LLC’s AlchemXE® chemically crosslinked ultra-high molecular weight polyethylene (UHMWPE) technology. According to the company, AlchemXE “blends dicumyl peroxide and vitamin E with UHMWPE during consolidation, then uses proprietary technology to crosslink the material, resulting in high wear resistance and excellent long-term oxidative stability without the need for radiation crosslinking.”

Additionally, a “proprietary heat treatment improves the mechanical properties and reduces the by-products of the peroxide chemistry.”

Referring back to the 510(k) summary document, the purpose of the application was to “add Klassic Knee CR/Congruent Tibial Inserts and Ultra-PS® Tibial Inserts, which are fabricated with E^X Poly, to the Klassic Knee System. E^X Poly is a crosslinked UHMWPE containing alpha-tocopherol. The subject Klassic Knee CR/Congruent and Ultra-PS Tibial Inserts are available in various sizes and thicknesses to match patient anatomy.”

Advertisement

In order to qualify for the shorter and earlier 510(k) clearance the device must be substantially equivalent to a predicate device. Here, the Klassic Knee CR/Congruent and Ultra-PS Tibial Inserts with E^X Poly are substantially equivalent to the “primary predicate Klassic Knee System Tibial Inserts with E-link Poly with respect to indications, material, design, and function.”

Alchimist is a medical device technology company. It develops materials to improve the performance of orthopedic implants.

Restoration Medical Polymers, based in Columbia City, Indiana, develops and tests implantable polymers for the orthopedic industry. Alchimist partnered with Restoration Medical Polymers to develop and produce its novel UHMWPE technology.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy